BrainStorm Cell Therapeutics

BCLIPhase 3

BrainStorm Cell Therapeutics is dedicated to defeating neurodegenerative diseases through its innovative NurOwn® autologous cellular technology platform. The company's lead program targets ALS, with a Phase 3b trial underway under an FDA Special Protocol Assessment (SPA). BrainStorm leverages proprietary methods to engineer a patient's own mesenchymal stem cells to secrete high levels of neurotrophic factors, aiming to slow disease progression.

Market Cap

$2.2B

Focus

Cell & Gene Therapy

BCLI · Stock Price

USD 200.25+76.50 (+61.82%)

Historical price data

AI Company Overview

Technology Platform

The NurOwn® platform is an autologous cellular technology that differentiates a patient's own mesenchymal stem cells to secrete high levels of neurotrophic factors (MSC-NTF cells) for targeted delivery to sites of neural damage.

Pipeline Snapshot

7 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Debamestrocel - MSC-NTF (NurOwn) + Placebo	Amyotrophic Lateral Sclerosis (ALS)	Phase 3
NurOwn® (MSC-NTF cells)	Amyotrophic Lateral Sclerosis (ALS)	Phase 3
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separat...	Amyotrophic Lateral Sclerosis	Phase 2
Nurown MSC-NTF cells + Placebo	Amyotrophic Lateral Sclerosis (ALS)	Phase 2
NurOwn (MSC-NTF cells)	Multiple Sclerosis, Chronic Progressive	Phase 2

Opportunities

Approval in ALS would address a devastating disease with high unmet need and establish the NurOwn® platform.

Success could enable expansion into other large neurodegenerative markets like Multiple Sclerosis, Alzheimer's, and Parkinson's disease.

Partnerships or out-licensing could accelerate development and provide non-dilutive funding.

Risk Factors

The company faces high clinical risk as its lead program's success depends on a single Phase 3b trial.

Financial risk is acute as a pre-revenue public company requiring continuous capital raises.

Autologous cell therapy presents complex manufacturing and scalability challenges.

Competitive Landscape

Competes in the ALS market with approved drugs (riluzole, edaravone, AMX0035) and other biotechs like Cytokinetics. Differentiates as an autologous cell therapy designed for disease modification via localized delivery of multiple neurotrophic factors, a unique mechanism compared to small molecules.